23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Gilead Sciences, Inc. › 2025-2026

Gilead Sciences, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Gilead Sciences, Inc.’s Form 8-K, filed May 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 15Ballot items
  • 1,382Asset managers, any item
  • 23,819Fund votes
  • April 30, 2026Meeting date

Results at a glance

Meeting of April 30, 2026: 15 items on Gilead Sciences, Inc.’s Form 8-K, filed May 4, 2026: 3 approved · 9 passed (calculated) · 3 not approved.

Dissent

Significant dissent: 1 shareholder proposal (27.1% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Gilead Sciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Gilead Sciences, Inc.

These tallies are Gilead Sciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Gilead Sciences, Inc. — official shareholder meeting results, meeting held April 30, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jacqueline K. Barton, Ph.D. 1,013,176,69621,056,724938,657 --95,008,389 98%Passed (calculated)—
Elect Director: Jeffrey A. Bluestone, Ph.D. 1,017,337,14916,873,041961,887 --95,008,389 98%Passed (calculated)—
Elect Director: Sandra J. Horning, M.D. 1,002,426,85831,078,6191,666,600 --95,008,389 97%Passed (calculated)—
Elect Director: Kelly A. Kramer 995,947,85438,240,224983,999 --95,008,389 96%Passed (calculated)—
Elect Director: Ted W. Love, M.D. 1,016,607,68817,592,385972,004 --95,008,389 98%Passed (calculated)—
Elect Director: Harish Manwani 995,710,46838,469,820991,789 --95,008,389 96%Passed (calculated)—
Elect Director: Daniel P. O'Day 980,597,21250,179,9854,394,880 --95,008,389 95%Passed (calculated)—
Elect Director: Javier J. Rodriguez 1,019,197,78315,002,200972,094 --95,008,389 99%Passed (calculated)—
Elect Director: Anthony Welters 992,619,89740,842,6461,709,534 --95,008,389 96%Passed (calculated)—
Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal 1,046,350,56982,831,295998,602 ---- 93%Approved—
Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal 954,325,80577,503,9473,342,325 --95,008,389 92%Approved—
Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal 970,290,58662,501,4332,380,058 --95,008,389 94%Approved—
Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal 280,044,780752,716,2252,411,072 --95,008,389 27%Not approved—
Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal 134,042,210886,986,58414,143,283 --95,008,389 13%Not approved—
Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal 7,262,4211,022,330,1865,579,470 --95,008,389 0.7%Not approved—

Source: Gilead Sciences, Inc., Form 8-K, filed with the SEC on May 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Gilead Sciences, Inc. 2025-2026 meeting

1,382 asset managers disclosed a vote on at least one Gilead Sciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Jacqueline K. Barton, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 10 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 1,013,176,696AGAINST: 21,056,724

Prior year: 98.0% for (May 7, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jacqueline K. Barton, Ph.D.”): 1,013,176,696 for, 21,056,724 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,643,431 for, 269 against, 126,542 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,643,431AGAINST: 269ABSTAIN: 126,542UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,764,040269 110For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Jeffrey A. Bluestone, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 13 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 1,017,337,149AGAINST: 16,873,041

Prior year: 98.4% for (May 7, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jeffrey A. Bluestone, Ph.D.”): 1,017,337,149 for, 16,873,041 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,643,486 for, 216 against, 126,542 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,643,486AGAINST: 216ABSTAIN: 126,542UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,764,095216 110For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Sandra J. Horning, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 13 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 1,002,426,858AGAINST: 31,078,619

Prior year: 97.1% for (May 7, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 1,002,426,858 for, 31,078,619 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,599,363 for, 44,330 against, 126,553 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,599,363AGAINST: 44,330ABSTAIN: 126,553UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,763,923379 220For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Kelly A. Kramer

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 10 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 995,947,854AGAINST: 38,240,224

Prior year: 97.1% for (May 7, 2025 meeting) ▼ 0.8 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Kelly A. Kramer”): 995,947,854 for, 38,240,224 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,552,940 for, 90,761 against, 126,543 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,552,940AGAINST: 90,761ABSTAIN: 126,543UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,763,840470 120For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Ted W. Love, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 13 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 1,016,607,688AGAINST: 17,592,385

Prior year: 98.4% for (May 7, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 1,016,607,688 for, 17,592,385 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,643,503 for, 200 against, 126,542 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,643,503AGAINST: 200ABSTAIN: 126,542UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,764,112200 110For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Harish Manwani

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 10 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 995,710,468AGAINST: 38,469,820

Prior year: 96.2% for (May 7, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Harish Manwani”): 995,710,468 for, 38,469,820 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,102,308 for, 541,395 against, 126,543 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,102,308AGAINST: 541,395ABSTAIN: 126,543UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,763,811501 120For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Javier J. Rodriguez

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 10 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 1,019,197,783AGAINST: 15,002,200

Prior year: 98.4% for (May 7, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Javier J. Rodriguez”): 1,019,197,783 for, 15,002,200 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,653,512 for, 190 against, 126,542 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,653,512AGAINST: 190ABSTAIN: 126,542UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,764,121190 110For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Anthony Welters

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 10 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 992,619,897AGAINST: 40,842,646

Prior year: 96.8% for (May 7, 2025 meeting) ▼ 0.7 pts

Details: description as filed, official tally, votes by 242 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Anthony Welters”): 992,619,897 for, 40,842,646 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 242 asset managers below reported 505,578,318 for, 65,873 against, 126,553 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,578,318AGAINST: 65,873ABSTAIN: 126,553UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,763,764536 220For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,7070 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).

Elect Director: Daniel P. O'Day

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 10 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 980,597,212AGAINST: 50,179,985

Prior year: 93.8% for (May 7, 2025 meeting) ▲ 1.3 pts

Details: description as filed, official tally, votes by 241 asset managers

Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day

Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Daniel P. O'Day”): 980,597,212 for, 50,179,985 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 241 asset managers below reported 505,517,311 for, 129,286 against, 126,590 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 505,517,311AGAINST: 129,286ABSTAIN: 126,590UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until th” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,763,633629 590For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,600107 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 241 asset managers. All 241 are in the interactive database (link above).

Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 970,290,586AGAINST: 62,501,433
Details: description as filed, official tally, votes by 251 asset managers

Description as filed by funds: To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:”): 970,290,586 for, 62,501,433 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (11 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Adopt Incentive Stock Option Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 251 asset managers below reported 501,397,474 for, 4,598,509 against, 126,949 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 501,397,474AGAINST: 4,598,509ABSTAIN: 126,949UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,763,639652 320For
Fidelity78,590,1150 00For
Capital Group67,499,6430 3860For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,499208 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,760,3320 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century03,393,694 00Against
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 251 asset managers. All 251 are in the interactive database (link above).

Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 30 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 954,325,805AGAINST: 77,503,947

Prior year: 91.2% for (May 7, 2025 meeting) ▲ 1.3 pts

Details: description as filed, official tally, votes by 1,375 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:”): 954,325,805 for, 77,503,947 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on Pay” (4 managers, 13,649 for, 120,181 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 228 asset managers voting on “To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy S” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,763,2741,005 450For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,241,7260 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,499208 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,759,3261,006 00For
Columbia Threadneedle4,563,0610 00For
MFS04,442,896 00Against
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,874,1450 00For
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Fund voting reports, all 228 managers: 499,502,891 for, 5,335,772 against, 126,576 abstained, 946 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1,185 asset managers voting on “To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy S” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity64,806,7690 00For
BlackRock58,910,2655,676 00For
Capital Group42,193,2720 3860For
Invesco41,411,35140 20For
State Street38,403,415429,258 00For
GEODE CAPITAL MANAGEMENT, LLC29,515,8090 00For
T. Rowe Price28,823,28512,003 00For
Capital Research Global Investors28,581,3730 00For
Dodge & Cox24,231,6660 00For
Vanguard13,028,2130 00For
Wellington12,642,2070 00For
Northern Trust11,478,345100,015 00For
UBS8,446,8140 00For
Charles Schwab8,337,6740 00For
Nuveen7,605,658260 00For
MELLON INVESTMENTS Corp6,831,5830 00For
Legal & General Investment Management Ltd130,7116,140,978 00Against
Goldman Sachs6,218,5750 00For
Amundi06,203,061 00Against
MASSACHUSETTS FINANCIAL SERVICES CO /MA/06,048,355 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC5,303,1730 00For
AllianceBernstein5,015,2880 00For
NORDEA INVESTMENT MANAGEMENT AB04,645,927 00Against
WELLS FARGO CLEARING SERVICES, LLC4,587,6510 00For
TD ASSET MANAGEMENT INC3,940,9250 00For

Institutional-manager reports, all 1,185 managers: 615,044,506 for, 57,872,075 against, 1,194,351 abstained, 344,414 not voted, 4,006 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 1,046,350,569AGAINST: 82,831,295

Prior year: 93.0% for (May 7, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 239 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following vote”): 1,046,350,569 for, 82,831,295 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (7 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 239 asset managers below reported 502,736,904 for, 2,368,674 against, 126,541 abstained, 942 not voted, 4,006 unknown.

FOR
FOR: 502,736,904AGAINST: 2,368,674ABSTAIN: 126,541UNKNOWN: 4,006NOT VOTED: 942
Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fisc” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,652,852111,460 100For
Fidelity78,590,1150 00For
Capital Group67,499,6430 00For
BlackRock49,234,5887,138 00For
Invesco38,663,9910 00For
Dodge & Cox19,998,3920 00For
JPMorgan15,929,4480 00For
State Street14,747,499208 00For
T. Rowe Price13,108,3140 00For
Charles Schwab7,852,5080 00For
TIAA6,806,8030 00For
Hartford4,759,3261,006 00For
Columbia Threadneedle4,563,0610 00For
MFS4,442,8960 00For
American Century3,393,6940 00For
Pacer Funds Trust3,288,5100 00For
First Trust3,054,8800 00For
Jackson National2,598,683275,462 00Mixed
Dimensional2,697,1140 00For
John Hancock2,429,7330 00For
WisdomTree2,216,5630 00For
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares1,945,9650 00For
Waddell & Reed1,945,3390 00For
MASTER INVESTMENT PORTFOLIO1,914,3330 00For

Showing the 25 largest of 239 asset managers. All 239 are in the interactive database (link above).

Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive…

Official resultDIVERSITY, EQUITY, AND INCLUSIONReported outcome: Not approved

Combines 8 wordings of this item as funds reported it.

0.7% Not approved · of votes cast

AGAINST
FOR: 7,262,421AGAINST: 1,022,330,186
Details: description as filed, official tally, votes by 255 asset managers

Description as filed by funds: To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes:”): 7,262,421 for, 1,022,330,186 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics.”
Support: 0.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 255 asset managers below reported 596,912 for, 505,599,598 against, 919,280 abstained, 942 not voted, 4,108 unknown.

AGAINST
FOR: 596,912AGAINST: 505,599,598ABSTAIN: 919,280UNKNOWN: 4,108NOT VOTED: 942
Largest asset managers voting on “To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metri” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard73114,764,176 740Against
Fidelity078,590,115 00Against
Capital Group067,499,643 00Against
BlackRock049,241,726 00Against
Invesco038,663,991 00Against
Dodge & Cox019,998,392 00Against
JPMorgan015,929,448 00Against
State Street014,747,707 00Against
T. Rowe Price013,108,314 00Against
Charles Schwab07,852,508 00Against
TIAA06,806,803 00Against
Hartford04,760,332 00Against
Columbia Threadneedle04,563,061 00Against
MFS04,442,896 00Against
American Century03,393,694 00Against
Pacer Funds Trust03,288,510 00Against
First Trust03,054,880 00Against
Jackson National02,874,145 00Against
Dimensional02,697,114 00Against
John Hancock02,429,733 00Against
WisdomTree02,216,563 00Against
INVESTMENT CO OF AMERICA01,947,854 00Against
ProShares01,945,965 00Against
Waddell & Reed01,945,339 00Against
MASTER INVESTMENT PORTFOLIO01,914,333 00Against

Showing the 25 largest of 255 asset managers. All 255 are in the interactive database (link above).

Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent…

Official resultOTHER SOCIAL ISSUESReported outcome: Not approved

Combines 5 wordings of this item as funds reported it.

13% Not approved · of votes cast

13%AGAINST
FOR: 134,042,210AGAINST: 886,986,584
Details: description as filed, official tally, votes by 241 asset managers

Description as filed by funds: To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes:”): 134,042,210 for, 886,986,584 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access.”
Support: 13% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 241 asset managers below reported 4,790,155 for, 499,983,082 against, 981,102 abstained, 942 not voted, 102 unknown.

AGAINST
FOR: 4,790,155AGAINST: 499,983,082ABSTAIN: 981,102NOT VOTED: 942UNKNOWN: 102
Largest asset managers voting on “To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patien” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard111,895114,652,237 1890Against
Fidelity078,590,115 00Against
Capital Group067,499,643 00Against
BlackRock29,61949,212,107 00Against
Invesco038,663,991 00Against
Dodge & Cox019,998,392 00Against
JPMorgan015,929,448 00Against
State Street4,06514,743,642 00Against
T. Rowe Price013,108,314 00Against
Charles Schwab07,852,508 00Against
TIAA06,806,803 00Against
Hartford1,0064,759,326 00Against
Columbia Threadneedle04,563,061 00Against
MFS04,442,896 00Against
American Century03,393,694 00Against
Pacer Funds Trust03,288,510 00Against
First Trust03,054,880 00Against
Jackson National02,874,145 00Against
Dimensional02,697,114 00Against
John Hancock02,429,733 00Against
WisdomTree02,216,563 00Against
INVESTMENT CO OF AMERICA01,947,854 00Against
ProShares01,945,965 00Against
Waddell & Reed01,945,339 00Against
MASTER INVESTMENT PORTFOLIO01,914,333 00Against

Showing the 25 largest of 241 asset managers. All 241 are in the interactive database (link above).

Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal

Official resultCORPORATE GOVERNANCEReported outcome: Not approved

Combines 3 wordings of this item as funds reported it.

27% Not approved · of votes cast

FOR 27%AGAINST
FOR: 280,044,780AGAINST: 752,716,225
Details: description as filed, official tally, votes by 234 asset managers

Description as filed by funds: To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.

Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes:”): 280,044,780 for, 752,716,225 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy.”
Support: 27% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Require Independent Board Chair” (11 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 234 asset managers below reported 85,108,391 for, 419,083,408 against, 126,559 abstained, 942 not voted, 102 unknown.

FORAGAINST
FOR: 85,108,391AGAINST: 419,083,408ABSTAIN: 126,559NOT VOTED: 942UNKNOWN: 102
Largest asset managers voting on “To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the A” at Gilead Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard114,057114,650,238 280Against
Fidelity576,50078,013,615 00Against
Capital Group67,499,6430 00For
BlackRock36,17249,205,554 00Against
Invesco038,663,991 00Against
Dodge & Cox019,998,392 00Against
JPMorgan015,929,448 00Against
State Street4,06514,743,642 00Against
T. Rowe Price013,108,314 00Against
Charles Schwab2,1127,850,397 00Against
TIAA06,806,803 00Against
Hartford1,0064,759,326 00Against
Columbia Threadneedle4,563,0610 00For
MFS04,442,896 00Against
American Century03,393,694 00Against
Pacer Funds Trust03,288,510 00Against
First Trust03,054,880 00Against
Jackson National02,874,145 00Against
Dimensional02,697,114 00Against
John Hancock1,843,756585,977 00Mixed
WisdomTree02,216,563 00Against
INVESTMENT CO OF AMERICA1,947,8540 00For
ProShares01,945,965 00Against
Waddell & Reed01,945,339 00Against
MASTER INVESTMENT PORTFOLIO01,914,333 00Against

Showing the 25 largest of 234 asset managers. All 234 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 2 items from the meeting of May 7, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest Gilead Sciences, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,242,000,000 shares outstanding at the time of that meeting.

Fund voting reports: top Gilead Sciences, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our Named Executive Officers as presented…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.24%
2Fidelity 6.33%
3Capital Group 5.43%
4BlackRock 3.96%
5Invesco 3.11%
6Dodge & Cox 1.61%
7JPMorgan 1.28%
8State Street 1.19%
9T. Rowe Price 1.06%
10Charles Schwab 0.63%
Institutional-manager reports: top Gilead Sciences, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our Named Executive Officers as presented…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 5.22%
2BlackRock 4.74%
3Capital Group 3.40%
4Invesco 3.33%
5State Street 3.13%
6GEODE CAPITAL MANAGEMENT, LLC 2.38%
7T. Rowe Price 2.32%
8Capital Research Global Investors 2.30%
9Dodge & Cox 1.95%
10Vanguard 1.05%

Reported Gilead Sciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Gilead Sciences, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
The Vanguard Group111,820,711 9.00%Proxy statement (DEF 14A), proxy filed March 20, 2026
BlackRock, Inc.101,739,273 8.19%Proxy statement (DEF 14A), proxy filed March 20, 2026
FMR LLC65,539,477 5.28%Schedule 13G, filed February 5, 2026
State Street59,858,585 4.82%Form 13F, quarter ended March 31, 2026
JPMorgan Chase33,992,410 2.74%Form 13F, quarter ended March 31, 2026
Gilead Sciences, Inc.31,424,760 2.53%Schedule 13D, filed August 7, 2026
Geode Capital29,726,052 2.39%Form 13F, quarter ended March 31, 2026
T. Rowe Price26,248,108 2.11%Form 13F, quarter ended March 31, 2026
Morgan Stanley23,512,734 1.89%Form 13F, quarter ended March 31, 2026
Invesco15,526,336 1.25%Form 13F, quarter ended March 31, 2026

Percentages above are of 1,242,000,000 shares outstanding, as reported by Gilead Sciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Gilead Sciences, Inc.'s shareholder meeting held April 30, 2026, in the 2025-2026 proxy season, 1,382 asset managers reported votes on at least one of its 15 ballot items in their SEC Form N-PX filings, covering 23,819 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our Named Executive Officers as presented… — Gilead Sciences, Inc.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Gilead Sciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Gilead Sciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Gilead Sciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Gilead Sciences (GILD) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/gilead-sciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.